Claude Leclerc

The malignant transformation of cells translates into a major worldwide health, social and economic burden. Efforts to define the etiology of cancer, along with the development of new therapeutic approaches to treat them, would […]

We are member of the ADITEC Consortium, a collaborative research programme that aims to accelerate the development of novel and powerful immunisation technologies for the next generation of human vaccines. Scientists from 13 countries […]

The purpose of this call for ideas is to solicit community input for original, cutting-edge science investigations that are consistent with the Institut Pasteur’s new development strategy in vaccinology. The “Open Pasteur vaccine challenge” […]

With the second call, the GPF Vaccinology aims at identifying ongoing preclinical projects aiming to develop vaccine candidates at Institut Pasteur, including the International Network. The objective of the GPF call is to help […]

Within the framework of developing a carbohydrate-based vaccine against cancer, we designed and prepared the MAG-Tn3, a fully synthetic immunogen based on the tumor-associated Tn antigen. The MAG-Tn3 is a glycopeptide associating Tn clusters […]

The Center for Translational Science, the Center Medical Institut Pasteur (CMIP) and the major federating program (GPF) vaccinology welcome for one year a science illustrator, Celia Ducaju, in partnership with the Ecole Estienne School […]

CyaA-based therapeutic cancer vaccines Based on our discovery that a bacterial protein, the adenylate cyclase (CyaA), binds to dendritic cells (DCs), we have developed a highly efficient vector capable of targeting a wide range […]

Human Papillomaviruses (HPV) are the major cause of human cervical cancer. We have developed a therapeutic tumor vaccine, the CyaA-E7 vaccine, that can induce specific responses against the HPV E7 oncoprotein and eliminate E7 […]